Long-term efficacy of pitavastatin versus simvastatin

Eriksson, Mats; Budinski, Dragos; Hounslow, Neil

doi:10.1007/s12325-011-0057-6

Cited by 28 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analyses excluding the INTREPID study were also conducted due to the special characteristics of its population (HIV individuals); this trial had, in addition, two time points for outcome evaluation (12 and 52 weeks) and both were explored. Finally, sensitivity analyses were performed including a subset of patients (n ¼ 168) from Eriksson et al (12-week follow-up) that continued for an extended follow-up to 44 weeks (randomization was maintained in this extended period) [27].…”

Section: Discussionmentioning

confidence: 99%

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

et al. 2015

View full text Add to dashboard Cite

“…Two papers presented data from the same study, which consisted of a 12-week initial treatment period (the core study) 9 followed by a 44-week extension. 10 Jadad scores were high (>3) for these studies except for one (Jadad score 2) which was open-label. 13 Study characteristics and quality assessment are summarized in Table 1 .…”

Section: Resultsmentioning

confidence: 80%

“…The long-term effects of statins (44 weeks) on percent change in LDL cholesterol concentrations compared with baseline were only presented in the study by Ericksson et al 10 Similar effects were observed for pitavastatin 4 mg (n=120) and simvastatin 40 mg (n=57; −41.81±15.1 versus −41.37±16.4, respectively).…”

Section: Resultsmentioning

confidence: 83%

“…Pitavastatin was more effective in lowering total cholesterol (2 mg, 12 weeks) and triglycerides (4 mg, 12 weeks) as compared with simvastatin (20 and 40 mg, 12 weeks; total cholesterol, P =0.041; triglycerides, P =0.044). 8 , 10 No statistically significant differences were observed in other secondary outcomes between pitavastatin and simvastatin. Secondary outcome data are summarized in Table 2 .…”

Section: Resultsmentioning

confidence: 96%

See 1 more Smart Citation

Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials

Ma¹,

Cui²

2015

DDDT

View full text Add to dashboard Cite

BackgroundSimvastatin is a statin used to lower low-density lipoprotein cholesterol, but has limitations in patients on complicated regimens due to concerns about drug-drug interactions. Pitavastatin is a newly developed statin with limited drug-drug interactions. We conducted a meta-analysis to compare the clinical efficacy of simvastatin and pitavastatin in the control of hypercholesterolemia.MethodsRandomized clinical trials comparing the efficacy of pitavastatin and simvastatin were identified by searching PubMed (2000–2014) and EMBASE (2000–2014). The primary outcome subjected to meta-analysis was percent change in low-density lipoprotein cholesterol compared with baseline.ResultsFour clinical trials were selected for meta-analysis. A total of 908 patients treated with pitavastatin (2 or 4 mg/day) and 381 patients treated with simvastatin (20 or 40 mg/day) were included in the final statistical analysis. No statistically significant difference was identified between treatment with pitavastatin 4 mg/day and treatment with simvastatin 40 mg/day for 12 weeks (mean difference −0.66; 95% confidence interval −2.92, 1.61; P=0.57). Similarly, no statistically significant difference was observed between pitavastatin 2 mg/day and simvastatin 20 mg/day for 4 weeks (mean difference −2.19; 95% confidence interval −0.11, 4.49; P=0.06). Treatment with pitavastatin was noninferior to simvastatin in all of the secondary outcomes and the safety profile was similar between the two statins.ConclusionPitavastatin is noninferior to simvastatin in lowering low-density lipoprotein cholesterol.

show abstract

“…Pitavastatin was no less effective than atorvastatin and simvastatin in presumed equipotent dosages, and was superior to pravastatin, in lowering LDL-C levels [ 18 , 19 ]. Pitavastatin provided sustained LDL-C-lowering efficacy and was associated with short- and longer-term improvements in several other lipid parameters [ 20 , 21 ]. Short- and longer-term outcomes in studies on Asian patients were consistent with these findings [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial

Kang

Kim

Park

et al. 2020

JCM

View full text Add to dashboard Cite

This study aimed to evaluate the efficacy of pitavastatin pretreatment on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) after a coronary procedure. This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial. All consecutive 70 patients with CKD (eGFR < 60 mL/min/1.73 m2) were enrolled and randomized into two groups. Group I consisted of patients who were treated with statins (pitavastatin 4 mg/day) for seven days before and three days after the procedure (n = 37, 52.9%), and group II consisted of patients who were treated with a placebo (n = 33, 47.1%). The primary endpoint was the incidence of CIN, and the secondary endpoints were the change in serum creatinine (∆sCr) level and estimated glomerular filtration rate (∆eGFR) after the procedure. The mean age of the patients (males, 74%) was 70.4 ± 9.0 years. After the coronary procedure, the incidence of CIN was lower in group I than in group II, but the difference was not significant (5.4% vs. 9.1%, p = 0.661). The maximal ∆sCr was lower and the maximal ∆eGFR was higher in group I than in group II, but the difference was not significant (−0.11 ± 0.53 mg/dL and −0.04 ± 0.33 mg/dL, p = 0.678; 4.3 ± 11.2 mL/min/1.73 m2 and −2.9 ± 20.4 mL/min/1.73 m2, p = 0.161, respectively). This study showed the possibility of a clinical benefit of pretreatment with a high dose of pitavastatin for the prevention of CIN in patients with CKD after coronary procedure (ClinicalTrials.gov Identifier: NCT01871792).

show abstract

Long-term efficacy of pitavastatin versus simvastatin

Cited by 28 publications

References 19 publications

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes

Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials

Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial

Contact Info

Product

Resources

About